Table 7.

Applied evaluations using the capability approach in their economic evaluations

Capability measure	Disease	Time points	Other HE measures	Changes in QALYs vs. capability values	Presentation of results	Reference
ICECAP-A	Visual impairment	Baseline; 2–4 months	EQ-5D-5L	Nearly identicala	Cost per Year of Full Capability (YFC)	[111]
	Diabetic plantar ulceration	Baseline; 6 months	EQ-5D-5L	QALYs negative; Capability positive	Cost and outcome data presented separately	[43]
	Drug addiction	Baseline; 12 months	EQ-5D-5L	Full capability higher than Sufficient capability, and both higher than QALYs	Years of full capability (YFC), years of sufficient capability equivalent (YSC)	[112]
	Schizophrenia	Baseline; 12–36–48 weeks	EQ-5D-3L	Nearly identicala	Cost and outcome data presented separately	[44]
ICECAP-O	Health decline in the older people	Baseline; 3 months	EQ-5D-3L	QALYs positive; Capability negative	Incremental net monetary benefit (INMB) regressions based on capability QALYs	[31]
	Heart failure, chronic obstructive pulmonary disease, or diabetes	Baseline; 12 months	EQ-5D-3L	Nearly identicala	Willingness to pay for 100% improvement in capability	[113]
	Visual impairment	3 months; post-intervention; pre-study	EQ-5D-5L	Capability higher than QALYs	Costs per years of well-being	[46]
	Hip fracture	Baseline; 3 months	EQ-5D-3L	Capability lower than QALYs	Cost and outcome data presented separately	[42]
OxCAP-MH	Psychosis	Baseline; 6–12 months	EQ-5D-3L	Nearly identicala	Cost and outcome data presented separately	[45]
ICECAP-A and OxCAP-MH	Schizophrenia or schizoaffective disorder and depression	Baseline, 3–6–9 months	EQ-5D-5L	QALYs positive; Capability: no significant change	Cost and outcome data presented separately	[114]

^aNearly identical means that the difference between baseline and follow-up are within a 10% range when comparing the QALYs and capability estimates